News | Sirnaomics

Press Release

Sirnaomics' 2022 annual results presentation will be held on 29 March 2023

2023.03.22

Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit

2023.03.20

RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting

2023.02.07

Sirnaomics in the News

MoCo biopharma Sirnaomics more than triples footprint with new HQ

2022-12

Exclusive: Sirnaomics hopes to develop non-melanoma skin cancer therapy with its siRNA

2022-09

Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year

2022-08

Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases

2022-08

After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology

2022-02

Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public

2021-07

RNA Silencing Finds Its Therapeutic Voice

2020-03

Hunt for New Coronavirus Treatments Includes Gene-Silencing And Monoclonal Antibodies

2020-02

Media Outreach

Sirnaomics Ltd.

401 Professional Dr, STE 280，Gaithersburg, MD 20879, USA

Alexis Feinberg

Tel: +1 203 939 2225